Ozempic has been used for type 2 diabetes since December 2017, when the U.S. Food and Drug Administration first approved it. That means it has been on the market for roughly seven years, making it a relatively well-established medication despite its recent surge in public attention.
FDA Approval and Early Use
The FDA granted initial approval for Ozempic (semaglutide) in 2017 as a once-weekly injection to improve blood sugar control in adults with type 2 diabetes. At launch, the available doses were 0.5 mg and 1 mg, given by self-injection with a prefilled pen. It entered a market that already included older drugs in the same class, called GLP-1 receptor agonists, but semaglutide stood out in clinical trials for its potency in lowering hemoglobin A1C, the standard measure of long-term blood sugar.
The European Commission followed a few months later, authorizing Ozempic across the European Union on February 8, 2018. Approvals in Canada, Australia, Japan, and other markets came around the same period, giving the drug a global footprint within about a year of its U.S. launch.
How Its Approved Uses Have Expanded
Ozempic’s label didn’t stay the same after that initial approval. In January 2020, the FDA added a significant new indication: reducing the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with type 2 diabetes who also have known heart disease. That expansion was based on a large trial showing semaglutide lowered cardiovascular risk in this group, not just blood sugar. For many patients and doctors, this made it more than a glucose-lowering drug.
Novo Nordisk also later introduced a higher 2 mg dose for patients who needed stronger blood sugar control beyond what the original doses provided. The oral form of semaglutide, sold under the brand name Rybelsus, received its own FDA approval in 2019, giving patients a daily pill option using the same active ingredient. And in 2021, a higher-dose version of semaglutide was approved specifically for weight management under the brand name Wegovy, though that is technically a separate product from Ozempic.
Why It Feels So New
If Ozempic has been around since 2017, you might wonder why it seems like everyone only started talking about it in 2023 or 2024. The answer is mostly about weight loss. Patients and doctors noticed early on that semaglutide caused significant weight reduction as a side effect, and once Wegovy was approved for obesity, public interest in all forms of semaglutide exploded. Celebrity use, social media, and widespread off-label prescribing for weight loss pushed Ozempic into mainstream conversation in a way that a diabetes drug rarely achieves.
That attention also created supply shortages that frustrated people who had been using Ozempic for diabetes management for years. The drug went from a well-regarded but relatively quiet diabetes treatment to one of the most talked-about medications in the world, all within a span of about two years.
Seven Years of Real-World Data
Seven years of use means doctors now have a substantial body of real-world evidence beyond the original clinical trials. The safety profile has been monitored across millions of prescriptions worldwide, and the most common side effects (nausea, vomiting, diarrhea, and constipation, especially when starting or increasing the dose) are well characterized. Rarer concerns, like a small increased risk of certain thyroid tumors seen in animal studies, continue to be tracked but have not led to changes in the drug’s approval status.
For context, many widely used diabetes medications went through a similar arc. Metformin was used in Europe for decades before the FDA approved it in 1995. Insulin analogs like glargine have been available since 2000. Ozempic is newer than both of those, but it is no longer a brand-new drug with limited track record. Endocrinologists generally consider it one of the more effective options currently available for type 2 diabetes, particularly for patients who also need to lose weight or have cardiovascular risk factors.
Patent Status and What Comes Next
Novo Nordisk’s U.S. patent on semaglutide is set to expire in 2032, which means generic or biosimilar versions are still several years away in the United States. In other markets, patent protections expire sooner, so competition could arrive earlier outside the U.S. Until then, Ozempic remains available only as a branded product, which affects its cost and accessibility for many patients.